Open Access<p>GM-CSF: A Promising Target in Inflammation and Autoimmunity</p>
Author(s) -
Kevin M.-C. Lee,
Adrian Achuthan,
John A. Hamilton
Publication year - 2020
Publication title -
immunotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 7
ISSN - 2253-1556
DOI - 10.2147/itt.s262566
Subject(s) - rheumatoid arthritis , immunology , granulocyte macrophage colony stimulating factor , inflammation , autoimmunity , cytokine , medicine , myeloid , antibody
The cytokine, granulocyte macrophage-colony stimulating factor (GM-CSF), was firstly identified as being able to induce in vitro the proliferation and differentiation of bone marrow progenitors into granulocytes and macrophages. Much preclinical data have indicated that GM-CSF has a wide range of functions across different tissues in its action on myeloid cells, and GM-CSF deletion/depletion approaches indicate its potential as an important therapeutic target in several inflammatory and autoimmune disorders, for example, rheumatoid arthritis. In this review, we discuss briefly the biology of GM-CSF, raise some current issues and questions pertaining to this biology, summarize the results from preclinical models of a range of inflammatory and autoimmune disorders and list the latest clinical trials evaluating GM-CSF blockade in such disorders.